ACR25 Best Abstracts - Day 2 Save

After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest pic.twitter.com/OyvnzEGlLE

— Richard Conway (@RichardPAConway) October 27, 2025

Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest pic.twitter.com/Xa97O6RdBY

— Antoni Chan MD (Prof) (@synovialjoints) October 27, 2025

Open label noninferiority RCT "METOGiA" in GCA

TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78

Everyone also got pred; are we sure MTX works at all?@RheumNow #ACR25 #ACRBest Abstr#0891 pic.twitter.com/i48JBnawB7

— Mike Putman (@EBRheum) October 27, 2025

Open-label MTX vs. Toci in GCA in METOGiA 

Wk 78: 
37% w/o relapse in MTX arm 
46% w/o relapse in Toci arm 

MTX was NOT non-inferior to Toci 
Toci superior in 2ndary endpoints

Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 pic.twitter.com/lCaP4EdJ9C

— Brian Jaros, MD (@Dr_Brian_MD) October 27, 2025

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest pic.twitter.com/G3tNQq8qXT

— Richard Conway (@RichardPAConway) October 27, 2025

In this ph2 trial of LEVI-04 for knee #osteoarthritis, 

At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades 

Promising treatment. #ACR25 @RheumNow Abs0852 #ACRBest pic.twitter.com/MrmLPlFiDs

— sheila (@RHEUMarampa) October 27, 2025